Effect of once-weekly teriparatide for bone metabolism in primary osteoprosis patients.
Not Applicable
- Conditions
- Osteoprosis
- Registration Number
- JPRN-UMIN000033118
- Lead Sponsor
- Kindai University Hospital, Department of Orthopaedic surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with diabetes, rheumatoid arthritis,respiratory,endocrinological and other disease and drug use that may affect bone metabolism were excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Observation of bone density and bone metabolism marker by treatment with Teriparatide during 18 months of treatment. Bone metabolism markers measure P1NP, TRAP-5b, osteocalcin, sclerostin. Bone density measures femur neck and lumbar spine.
- Secondary Outcome Measures
Name Time Method